Bristol-Myers Squibb declares 3.2% dividend increase

NewsGuard 100/100 Score

The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) today declared a 3.2 percent increase in the company’s quarterly dividend, beginning in the first quarter of 2010.

“This dividend increase reflects our ongoing commitment to deliver shareholder value”

“This dividend increase reflects our ongoing commitment to deliver shareholder value,” said James M. Cornelius, chairman and chief executive officer of Bristol-Myers Squibb. “We have made excellent progress in executing our strategy and we are confident in the strength of our BioPharma business. Our performance has helped put us in a strong cash position today and we expect solid cash flows to continue in the years ahead.”

The dividend increase will result in a quarterly dividend of thirty-two cents ($0.32) per share on the $.10 par value Common Stock of the corporation for an indicative 2010 full-year dividend of $1.28 per share, subject to the normal quarterly review by the Board. The next quarterly dividend will be payable on February 1, 2010 to stockholders of record at the close of business on January 4, 2010.

The Directors also declared a quarterly dividend of fifty cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable March 3, 2010 to stockholders of record at the close of business on February 8, 2010.

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.